{"entity":{"id":"nct05732831","kind":"trial","name":"Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of TNG462 and Pembrolizumab in advanced solid tumours, run by Tango Therapeutics, Inc., now recruiting.","summary":"Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors is a phase 1/2 interventional study registered as NCT05732831 by Tango Therapeutics, Inc., with 225 participants planned, started 2023-05-26 and due to reach its primary completion in 2027-06. Interventions recorded: TNG462 and Pembrolizumab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05732831","url":"https://clinicaltrials.gov/study/NCT05732831"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["tng462","pembrolizumab"],"companies":["tango-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05732831","phase":"1/2","setting":"A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 as a Single Agent and in Combination in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors","sponsor":"Tango Therapeutics, Inc.","enrolled":225,"outcomes":[]},"route":"/trials/nct05732831/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"tng462","kind":"drug","name":"TNG462","route":"/drugs/tng462/"}],"company":[{"id":"tango-therapeutics","kind":"company","name":"Tango Therapeutics","route":"/companies/tango-therapeutics/"}]}}